Composition, form of production and packaging
? Capsules of green color, oval; the contents of capsules - the mass of oily consistency from light brown to dark brown color, with a characteristic odor.
1 caps.
dry extract of fruits serenoi creeping (10-14.3: 1) * 160 mg
dry extract of the roots of the nettle (7.6-12.5: 1) ** 120 mg
* Extractor: ethanol 90%.
** Extractant: 60% ethanol.
Excipients: triglycerides (tri-esters of saturated glycerol C 8 -C 18 and fatty acids), soya hydrogenated oil, silicon dioxide colloid.
The composition of the capsule shell: glycerol 85% (glycerin), gelatin polysuccinate, iron oxide black (E172), iron oxide yellow (E172), patented blue V (E131).
20 pcs. - blisters (3) - packs of cardboard.
20 pcs. - blisters (6) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2016.
PHARMACHOLOGIC EFFECT
A preparation of vegetable origin, used in the treatment of benign prostatic hyperplasia. It has anti-inflammatory, anti-edematous, immunomodulating, anti-proliferative and anti-androgenic effects.
Anti-inflammatory and anti-edematous actions are caused by inhibition of the main links of the cascade of arachidonic acid and the synthesis of prostaglandins and leukotrienes, followed by a decrease in permeability and, as a consequence, a decrease in pain, inflammation and edema of the prostate tissue.
Immunomodulatory effect is due to suppression of autoimmune effects on prostate tissue in inflammatory processes, as well as to a decrease in the proliferation of active lymphocytes.
Antiproliferative and antiandrogenic actions are due to inhibition of the enzymes aromatase and 5-alpha-reductase, which prevents the formation of testosterone estradiol and dihydrotestosterone, which promote the growth of prostate tissue.
Prostagut forte reduces the symptoms of urination disorders due to benign prostatic hyperplasia. Reduces pain and burning sensation when urinating, promotes rapid emptying of the bladder and reduces the frequency of false and nocturnal urge to urinate.
Has no effect on sexual activity.
PHARMACOKINETICS
The action of the drug Prostagutte is the cumulative effect of its components, therefore it is not possible to carry out kinetic studies.
INDICATIONS
- disturbances of urination with benign prostatic hyperplasia of I and II degrees;
- Disorders of urination with prostatitis;
- prevention of recurrence of benign prostatic hyperplasia after surgery.
DOSING MODE
The drug is taken orally 1 capsule 2 times / day (morning and evening). Capsules should be swallowed without chewing and washing with a small amount of water.
The duration of treatment is at least 30 days.
SIDE EFFECT
Rarely: irritation of the mucous membrane of the stomach (when taking the drug on an empty stomach).
Possible: allergic reactions.
Prostagut forte is characterized by good tolerability.
CONTRAINDICATIONS
- Hypersensitivity to the components of the drug.
SPECIAL INSTRUCTIONS
It should be taken into account that the drug only reduces the severity of symptoms caused by an increase in the prostate gland, without eliminating the increase itself.Regular monitoring of the patient's clinical condition is necessary.
The patient should be warned that if there is blood in the urine and / or with an acute urinary retention, you should immediately call your doctor.
OVERDOSE
Currently, cases of overdose of the drug Prostagut forte have not been reported.
DRUG INTERACTION
Drug interaction of the drug Prostagut forte is not described.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children at a temperature of no higher than 30 В° C. Shelf life - 3 years.
